ENEA Munich
 

Scientific Programme

Download Programme (PDF)


Thursday December 1st - Friday December 2nd - Saturday December 3rd



Thursday December 1st

from 10.00 Registration
11.00-11.45 Pre-Symposium: Presentation of the AMORE Study
Chairs: Feng Gu (China), Luciana Naves (Brazil)
Annamaria Colao (Italy) on behalf of the Workshop and Study Committee
12.00-13.30 Novartis lunch symposium
"Cushing┤s Disease - How do new developments change daily practice?"
Chair: Christian J. Strasburger (Germany)
Stephan Petersenn (Germany): "Current developments in the diagnosis of Cushing┤s Disease"
Steven Lamberts (The Netherlands): "Current and new therapeutic options in Cushing┤s Disease"
Günter K. Stalla (Germany): "Status update of clinical trials with SOM230 in pituitary tumours"
13.30-14.00 Opening Remarks
Albert Beckers, ENEA Secretary
Annamaria Colao, WSC President
Günter Stalla, LOC
14.00-14.45 Lecture I
Chairs: Anton Luger (Austria), Jens Otto J°rgensen (Denmark)
Albert Beckers (Belgium): Genetics of pituitary tumors
14.45-15.45 Symposium I - Pathology & Diagnosis
Chairs: Federico Roncaroli (UK), Jacqueline Trouillas (France)
14.45-15.00 Wolfgang Saeger (Germany): Histopathological features of atypical adenomas and carcinomas of the pituitary
15.00-15.15 Niki Karavitaki (UK): Histopathological classification of craniopharyngiomas
15.15-15.30 Jean Franšois Bonneville (France): Agressive pituitary tumors: MRI diagnosis
15.30-15.45 Discussion
15.45-16.00 Coffee Break
16.00-17.15 Symposium II - Craniopharyngiomas
Chairs: Martin Reincke (Germany), Sabina Zacharieva (Bulgaria)
16.00-16.15 Adrian Daly (Belgium): The epidemiology of craniopharyngiomas
16.15-16.30 Emanuela Arvat (Italy): Endocrine symptoms
16.30-16.45 Eva Marie Erfurth (Sweden): Metabolic disturbances
16.45-17.00 Alberto Pereira (The Netherlands): Craniopharyngiomas - long-term consequences
17.00-17.15 Discussion
17.15-18.00 Lecture II
Chairs: Monica Gadelha (Brazil), Stelios Tsagarakis (Greece)
Thierry Brue (France): Pituitary carcinomas
18.00-18.15 Coffee Break
18.15-19.30 Symposium III - How to define aggressive growth hormone-secreting pituitary tumors?
Chairs: Christof Schöfl (Germany), Annamaria Spada (Italy)
18.15-18.30 Silvia Vandeva (Bulgaria): The epidemiology of aggressive GH-secreting pituitary tumors?
18.30-18.45 Andrea Lania (Italy): Markers of aggressiveness
18.45-19.00 Moises Mercado (Mexico): Clinical characteristics
19.00-19.15 Sebastian Neggers (The Netherlands): Response to therapy
19.15-19.30 Discussion
19.30-20.30 Get together party

Friday December 2nd

08.30-09.30 Symposium IV - How to define aggressive ACTH-secreting tumors?
Chairs: Marek Bolanowski (Poland), Christian Strasburger (Germany)
08.30-08.45 André Lacroix (Canada): Aggressive ACTH-producing pituitary tumors: Epidemiology and clinical characteristics
08.45-09.00 Maria Tichomirowa (Belgium): Markers of aggressiveness
09.00-09.15 Stephan Petersenn (Germany): Response to therapy
09.15-09.30 Discussion
09.30-10.30 Symposium V - How to define aggressive prolactin-secreting tumors and nonfunctioning pituitary tumors?
Chairs: Liudmila Rozhinskaya (Russia), Antonio Pico (Spain)
09.30-09.45 Vera Popovic (Serbia): Epidemiology and clinical characteristics
09.45-10.00 Ilan Shimon (Israel): Markers of aggressiveness
10.00-10.15 Philippe Caron (France): Response to therapy
10.15-10.30 Discussion
10.30-11.00 Coffee Break
11.00-12.00 Oral Communications I (basic/clinical)
Chairs: Gregory Kaltsas (Greece), Patrick Petrossians (Belgium)
11.00-11.10 Murine genetic approaches reveal novel evidence for the molecular and cellular aetiology of human adamantinomatous craniopharyngioma
Juan Pedro Martinez-Barbera (UK)
11.10-11.20 NVP-BEZ235 inhibits the survival of MENX-associated nonfunctioning pituitary adenomas andrequires p27 expression for best efficacy
Misu Lee (Germany)
11.20-11.30 Magmas, a novel over-expressed gene in Pituitary rat cell lines and in human pituitary adenomas: a new pituitary bio marker?
Maria Chiara Zatelli (Italy)
11.30-11.40 Dopastatin distinctly influences various functional endpoints in different types of pituitary adenomas: an in vitro study
Alejandro Ibá˝ez Costa (Spain)
11.40-11.50 Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia, severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations in acromegaly due to a therapeutically resistant pituitary GH-secreting macroadenoma
Valentina Guarnotta (Italy)
11.50-12.00 Aggressive pituitary adenomas: Incidence of O6-methylguanine DNA methyltransferase expression
Roberto Baldelli (Italy)
12.00-13.00 Symposium VI - Co-morbidities
Chairs: Jens B°llerslev (Norway), Richard Feelders (The Netherlands)
12.00-12.15 Henri Wallaschofski (Germany): Long-term GH replacement and safety
12.15-12.30 Philippe Chanson (France): Water and electrolyte disturbances
12.30-12.45 Carla Giordano (Italy): Glucose abnormalities
12.45-13.00 Discussion
13.00-13.30 Pfizer Key Note Lecture
Influence of treatments on tumour proliferation in acromegaly
Michael Buchfelder (Germany) Download Flyer (PDF)
13.30-14.00 Keynote Lecture Discussion and Lunch
14.00-15.00 Posterview
15.00-16.00 Symposium VII - Advances in surgery and radiotherapy
Chairs: Michael Buchfelder (Germany), Dominique Maiter (Belgium)
15.00-15.15 Paolo Cappabianca (Italy): Technical aspects of endoscopic endonasal surgery in aggressive pituitary tumors
15.15-15.30 Jürgen Honegger (Germany): Microsurgical treatment for craniopharyngiomas
15.30-15.45 Panagiotis Nomikos (Greece): Combined neurosurgical and radiosurgical treatment
15.45-16.00 Discussion
16.00-16.30 Coffee break
16.30-17.30 Symposium VIII - Medical treatment of aggressive pituitary tumors I
Chairs: Marco Boscaro (Italy), Fahrettin Kelestimur (Turkey)
16.30-16.45 Gérald Raverot (France): Octreotide and lanreotide
16.45-17.00 Rosario Pivonello (Italy): Pasireotide
17.00-17.15 Monica Marazuela (Spain): GH-receptor antagonist
17.15-17.30 Discussion
17.30-18.30 Symposium IX - Medical treatment of aggressive pituitary tumors II
Chairs: Roger Abs (Belgium), Miklos Goth (Hungary)
17.30-17.45 Yona Greenman (Israel): Treatment of aggressive pituitary tumors with dopamine-agonists
17.45-18.00 Alexandru Saveanu (France): Co-targeting somatostatin and dopamine receptors
18.00-18.15 Marco Losa (Italy): Temozolomide
18.15-18.30 Discussion
20.00 Bavarian Evening at the "Paulaner am Nockherberg"

Saturday December 3rd

08.30-09.30 Oral Communications II
Chairs: Davide Carvalho (Portugal), Elena Grineva (Russia)
08.30-08.40 Temozolomide in aggressive pituitary adenomas and carcinomas ľ the Erlangen experience
Sven-Martin Schlaffer (Germany)
08.40-08.50 Tumor recurrence and enlargement in patients with craniopharyngioma with and without growth hormone replacement therapy during more than 10 years of follow-up
Daniel S. Olsson (Sweden)
08.50-09.00 Markers of recurrence and long-term morbidity in craniopharyngiomas: a systematic analysis in 171 patients
Philippe Touraine (France)
09.00-09.10 10 Improvement in clinical signs and symptoms of Cushingĺs disease following 12 months pasireotide therapy
Rosario Pivonello on behalf of the Pasireotide B2305 Study Group
09.10-09.20 Clinical characterization of cabergoline resistant prolactinomas: A multicenter experience on 92 patients.
Laurent Vroonen (Belgium)
09.20-09.30 Complication rates after surgical treatment of aggressive and non-aggresive pituitary tumors
Kostas Lampropoulos (Greece)
09.30-10.15 Lecture III
Chairs:William Farrell (UK) Günter Stalla (Germany)
Ashley Grossman (UK): The molecular pathogenesis of pituitary tumors
10.15-11.15 Symposium X - Signaling defects and biomarkers
Chairs: Marcelo Bronstein (Brazil), Ulrich Renner (Germany)
10.15-10.30 Anne Barlier (France): Predictors of response to pharmacological treatment
10.30-10.45 Stefan Schulz (Germany): Immunohistochemistry to profile somatostatin receptors
10.45-11.00 Constantin Stratakis (USA): Pituitary tumors: Signaling defects and micro-RNAs
11.00-11.15 Discussion
11.15-11.30 Coffee Break
11.30-13.00 Symposium XI New pharmacological targets
Chairs: Justo Castano (Spain), Fatih Tanriverdi (Turkey)
11.30-11.45 Diego Ferone (Italy): Everolimus
11.45-12.00 Marily Theodoropoulou (Germany): Dual PIK3/mTOR inhibitors
12.00-12.15 Leo J Hofland (The Netherlands): Interferon(s) revisited
12.15-12.30 Márta Korbonits (UK): Unusual targets for unusual tumors
12.30-12.45 Maria Chiara Zatelli (Italy): Antibodies against growth factors
12.45-13.00 Discussion
13.00-13.30 Conclusion and Poster Prize
Marily Theodoropoulou, Scientific Coordinator on behalf of the Organizing Committee


Thursday December 1st - Friday December 2nd - Saturday December 3rd



 
 
© 2011-2019 EndoScience Endokrinologie Service GmbH - Hopfengartenweg 19 - 90518 Altdorf
URI: http://www.eneamunich.com/program.php